NEW YORK — Australian microbial genetics firm Microba said on Thursday that it has partnered with the University of Queensland to study the gut microbiome to identify novel biomarkers and treatments for Parkinson's disease.
According to Microba, research has linked changes in the gut microbiome with the onset of Parkinson's disease. Under the terms of the collaboration, the University of Queensland and Microba will use the company's metagenomic sequencing and analysis technologies to examine the link between the gut microbiome and Parkinson's disease in animal models and in patients.
The alliance's first human trial, which is being funded by the Queensland government and slated to begin later this year, aims to determine if an investigational treatment can restore beneficial gut microbiome species and improve symptoms such as constipation in Parkinson’s disease patients, Microba said.
Additional terms of the deal were not disclosed.